Trial Profile
A prospective cohort trial comparing Gallium-68-DOTATATE PET/CT with Indium-111-Octreotide Scintigraphy in patients with gastroenteropancreatic neuroendocrine tumors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Gallium 68-DOTATATE (Primary) ; Indium-111-octreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Diagnostic use
- 08 Jun 2016 New trial record